In non-small cell lung carcinoma (NSCLC), Cabozantinib showed higher efficacy in RET-fusion patients [37], leaving open the hypothesis that an inhibitor may have different efficacy against RET mutation and/or rearrangement. Here, RET is linked to non-small cell lung carcinoma.